Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ViR

Financiado

Cerrado

We are developing ground breaking therapeutics to cure currently untreatable res...

We are developing ground breaking therapeutics to cure currently untreatable respiratory infections affecting children and the elderly Human respiratory viruses cause economic and health burdens worldwide because there are no effective therapies. We have discovered a novel approach to stop their infection. The human respiratory viruses parainfluenza (PIV) and res... ver más

30/04/2019

ViRelieve

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

VIRELIEVE THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ViRelieve

50.00K€ | Lider

LABORATORIO FISH AND TECH

351.88K€ | Participante

Proyectos interesantes

SAF2009-11632

Medical Technol...

Biotechnology

456K€ Cerrado

OSIRIX

Medical Technol...

Biotechnology

4M€ Cerrado

BIO2013-42869-R

Medical Technol...

Public Health

397K€ Cerrado

PHA-ST-TRAIN-VAC

Medical Technol...

Pharmaceutical...

1M€ Cerrado

FLUCURE

Medical Technol...

Pharmaceuticals

8M€ Cerrado

DETECCIÓN SIMULTÁNEA DE CORONAVIRUS INFLUENZ...

Medical Technol...

Biotechnology

182K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 3 meses Fecha Inicio: 2019-01-30
Fecha Fin: 2019-04-30

Líder del proyecto

VIRELIEVE THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Human respiratory viruses cause economic and health burdens worldwide because there are no effective therapies. We have discovered a novel approach to stop their infection. The human respiratory viruses parainfluenza (PIV) and respiratory syncytial (RSV) viruses cause economic and health burdens worldwide. While RSV is the number one cause of death in children under 5 years old, with over 33M new cases occurring annually worldwide, PIV is the cause of 4-5% of all respiratory infections and 6-11% of all hospitalizations. However, currently there are no effective therapeutics to treat these debilitating infections and the economic burden associated with RSV and PIV is estimated at more than $11B annually, also defining a multi-billion dollar pharmaceutical market gap. We founded ViRelieve - biotech company with the main purpose to develop much-needed therapeutics to treat infections caused by RSV, PIV and related viruses. ViRelieve is led by an experienced team with biotech business, finance and IP expertise, drug development experience from pharmaceutical companies, and top researchers in virology and chemistry. We have discovered weaknesses in two processes essential for the virus infection – virus entry and replication, and have developed novel approaches to block these processes and thus stop these viruses from causing disease. Our R&D program has led to several patents filed and issued for unique compounds that specifically target essential virus components and demonstrated their effectiveness in animal models. Thus, our therapeutics will specifically treat RSV and PIV infections and will be superior to the few existing solutions as well as future competitors. In summary, gathering a complete expert team, filling patents, securing exclusive licenses and demonstrating the efficiency of our innovative therapeutics in animals makes us uniquely poised to succeed in our venture to deliver efficient drug candidates to clinical trials in a timely and effective manner.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores